The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug Aquipta (atogepant), marking a significant milestone in the prevention of migraine in adults with four or more migraine days per month. Aquipta becomes the first once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist to receive approval in the region for both chronic and episodic migraine.
Phase III Data Supports Approval
The decision by the EC is supported by robust Phase III data, which demonstrated that Aquipta significantly reduced mean monthly migraine days (MMDs) for the majority of participants. Furthermore, a significant portion of the trial’s participants achieved a reduction in MMDs of at least 50%, highlighting the drug’s potential impact on the quality of life for those suffering from migraines.
Global Reach of AbbVie’s Aquipta
AbbVie’s Aquipta already holds a similar indication in the US market and has been approved for episodic migraine in Canada and Mexico. The latest approval in Europe further expands the drug’s global footprint, offering a new treatment option for migraine sufferers across the continent.-Fineline Info & Tech
